PharmaResearch Co., Ltd. (KOSDAQ:214450)
South Korea
· Delayed Price · Currency is KRW 315,500
-17,500 (-5.26%)
At close: Mar 9, 2026
PharmaResearch Revenue
PharmaResearch had revenue of 135.43B KRW in the quarter ending September 30, 2025, with 51.81% growth. This brings the company's revenue in the last twelve months to 496.03B, up 56.48% year-over-year. In the year 2024, PharmaResearch had annual revenue of 350.12B with 34.14% growth.
Revenue (ttm)
496.03B
Revenue Growth
+56.48%
P/S Ratio
6.61
Revenue / Employee
998.04M
Employees
497
Market Cap
3,277.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 350.12B | 89.10B | 34.14% |
| Dec 31, 2023 | 261.01B | 66.25B | 34.02% |
| Dec 31, 2022 | 194.76B | 40.68B | 26.40% |
| Dec 31, 2021 | 154.08B | 45.34B | 41.69% |
| Dec 31, 2020 | 108.75B | 24.87B | 29.66% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SK bioscience | 624.03B |
| D&D Pharmatech | 8.36B |
| OliX Pharmaceuticals | 10.18B |
| Hugel | 425.10B |
| Orum Therapeutics | 25.48M |
| Voronoi | 7.49B |
| Peptron | 6.19B |
| Chabiotech | 1,197.69B |